Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)

E Hamilton; V Borges; R Murthy; C Anders; D Cameron; L Carey; V Müller; G Curigliano; K Gelmon; G Hortobagy; I Krop; S Loibl; X Pivort; M Pegram; D Slamon; S Hurvitz; M Tsai; E Winer

doi:10.1158/1538-7445.SABCS16-OT1-02-09

Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)

E Hamilton
, V Borges
, R Murthy
, C Anders
, D Cameron
, L Carey
, V Müller
, G Curigliano
, K Gelmon
, G Hortobagy
, I Krop
, S Loibl
, X Pivort
, M Pegram
, D Slamon
, S Hurvitz
, M Tsai
, E Winer

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	OT1-02-09-OT1-02-09
Journal	Cancer Research
Volume	77
Issue number	4 Supplement
DOIs	https://doi.org/10.1158/1538-7445.SABCS16-OT1-02-09
Publication status	Published - 14 Feb 2017

Access to Document

10.1158/1538-7445.SABCS16-OT1-02-09

http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS16-OT1-02-09

Cite this

Hamilton, E., Borges, V., Murthy, R., Anders, C., Cameron, D., Carey, L., Müller, V., Curigliano, G., Gelmon, K., Hortobagy, G., Krop, I., Loibl, S., Pivort, X., Pegram, M., Slamon, D., Hurvitz, S., Tsai, M., & Winer, E. (2017). Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB). Cancer Research, 77(4 Supplement), OT1-02-09-OT1-02-09. https://doi.org/10.1158/1538-7445.SABCS16-OT1-02-09

Hamilton, E ; Borges, V ; Murthy, R et al. / Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB). In: Cancer Research. 2017 ; Vol. 77, No. 4 Supplement. pp. OT1-02-09-OT1-02-09.

@article{38065e74da5f4312996c38ff18d6f558,

title = "Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)",

author = "E Hamilton and V Borges and R Murthy and C Anders and D Cameron and L Carey and V M{\"u}ller and G Curigliano and K Gelmon and G Hortobagy and I Krop and S Loibl and X Pivort and M Pegram and D Slamon and S Hurvitz and M Tsai and E Winer",

year = "2017",

month = feb,

day = "14",

doi = "10.1158/1538-7445.SABCS16-OT1-02-09",

language = "English",

volume = "77",

pages = "OT1--02--09--OT1--02--09",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research Inc.",

number = "4 Supplement",

}

Hamilton, E, Borges, V, Murthy, R, Anders, C, Cameron, D, Carey, L, Müller, V, Curigliano, G, Gelmon, K, Hortobagy, G, Krop, I, Loibl, S, Pivort, X, Pegram, M, Slamon, D, Hurvitz, S, Tsai, M & Winer, E 2017, 'Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)', Cancer Research, vol. 77, no. 4 Supplement, pp. OT1-02-09-OT1-02-09. https://doi.org/10.1158/1538-7445.SABCS16-OT1-02-09

Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB). / Hamilton, E; Borges, V; Murthy, R et al.
In: Cancer Research, Vol. 77, No. 4 Supplement, 14.02.2017, p. OT1-02-09-OT1-02-09.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB)

AU - Hamilton, E

AU - Borges, V

AU - Murthy, R

AU - Anders, C

AU - Cameron, D

AU - Carey, L

AU - Müller, V

AU - Curigliano, G

AU - Gelmon, K

AU - Hortobagy, G

AU - Krop, I

AU - Loibl, S

AU - Pivort, X

AU - Pegram, M

AU - Slamon, D

AU - Hurvitz, S

AU - Tsai, M

AU - Winer, E

PY - 2017/2/14

Y1 - 2017/2/14

U2 - 10.1158/1538-7445.SABCS16-OT1-02-09

DO - 10.1158/1538-7445.SABCS16-OT1-02-09

M3 - Meeting abstract

SN - 0008-5472

VL - 77

SP - OT1-02-09-OT1-02-09

JO - Cancer Research

JF - Cancer Research

IS - 4 Supplement

ER -

Hamilton E, Borges V, Murthy R, Anders C, Cameron D, Carey L et al. Abstract OT1-02-09: A phase 2 randomized, double-blinded, controlled study of ONT-380 vs. placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (MBC) (HER2CLIMB). Cancer Research. 2017 Feb 14;77(4 Supplement):OT1-02-09-OT1-02-09. doi: 10.1158/1538-7445.SABCS16-OT1-02-09